Shire plc: Shire plc: Director/PDMR Shareholding

Director/PDMR Shareholding

 

August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)

 

Notification of transaction by person discharging managerial responsibilities

 

1.	Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a)	Name	Flemming Ornskov
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - PDMR
b)	Initial notification / amendment	Initial notification
3.	Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)	Name	Shire plc
b)	LEI	54930005LQRLI2UXRQ59
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") Â
	Identification code	ISIN: JE00B2QKY057
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£36.6493	8,400
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
e)	Date of the transaction	August 22, 2017
f)	Place of the transaction	London Stock Exchange

 

Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:

Investor Relations	Â	Â
Ian Karp	[e-mail] (mailto:[e-mail])	[phone]
Robert Coates	[e-mail] (mailto:[e-mail])	[phone]
Media	Â	Â
Lisa Adler	[e-mail]	[phone]
Debbi Ford	[e-mail] (mailto:[e-mail])Â	[phone]

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com (http://www.shire.com/)

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via Globenewswire